Alzheimer’s Risk Gene BIN1 Acts as a Brake on Brain Inflammation

Deep inside the brain, a population of immune cells called microglia stands guard against infection, injury and the molecular debris of aging. In recent years, these cells have moved from the sidelines of Alzheimer’s research to its center stage, as genome-wide association studies repeatedly point to immune pathways as major drivers of the disease. Now, a new study published in Cellular and Molecular Life Sciences adds a crucial piece to that puzzle. A team led by Maria Margariti and Irini Thanou of the Hellenic Pasteur Institute in Athens, together with collaborators in France, Brazil and Switzerland, reports that BIN1, the second most important genetic risk locus for late-onset Alzheimer’s disease after APOE, functions within microglia as a critical restraint on inflammatory activation. When the protein is missing from these cells, the brain’s immune response to systemic inflammation becomes markedly exaggerated, shifting microglia toward a pro-inflammatory state that strikingly resembles the one observed in human Alzheimer’s tissue.

BIN1, short for Bridging Integrator 1, is an adaptor protein best known for its role in shaping cell membranes and regulating the dynamics of the cytoskeleton. In neurons, previous work has linked BIN1 to defects in intracellular transport, synaptic dysfunction and the accumulation of tau pathology, one of the hallmark protein abnormalities of Alzheimer’s disease. What has remained far less clear is what BIN1 does in microglia, the resident immune cells that account for a growing share of Alzheimer’s genetic risk. Because neuroinflammation is a defining feature of the disease, the researchers set out to determine whether microglial BIN1 influences the inflammatory tone of the brain, both in the healthy resting state and under conditions of immune challenge.

To answer that question, the team engineered mice in which the Bin1 gene could be deleted specifically in microglia, creating what researchers call a microglia-specific conditional knockout, or Bin1cKO, mouse. This approach matters because BIN1 is expressed in multiple brain cell types, and deleting it everywhere would make it impossible to attribute any observed effect to a single cell population. By restricting the deletion to microglia, the researchers could ask a precise question: does the loss of BIN1 within these immune cells alone change how the brain responds to inflammation? The experimental procedures were carried out in compliance with European and Greek legislation on laboratory animal use and approved by the Animal Care and Use Committee of the Hellenic Pasteur Institute.

The first analytical tool the team deployed was single-nucleus RNA sequencing, a technique that captures the gene expression profile of individual cell nuclei and allows researchers to identify distinct cellular states with unprecedented resolution. By profiling the brains of the Bin1cKO mice, the investigators discovered that the deletion of BIN1 did not leave microglia untouched even under normal, homeostatic conditions. Instead, the loss of the protein produced measurable alterations in microglial morphology, the intricate branching structure that these cells use to survey their environment, and shifted their inflammatory gene expression profile. In other words, removing BIN1 appeared to release the cells from a state of restraint, nudging them toward an activated phenotype before any external challenge had even occurred.

The most dramatic effects, however, emerged when the animals were subjected to systemic inflammation, an immune challenge elsewhere in the body that sends inflammatory signals cascading into the brain. Under these conditions, the Bin1cKO microglia proved sufficient to alter the expression of key genes that regulate microglial proliferation and pro-inflammatory activation. The researchers found that the response was driven largely by an enhancement of the type I interferon pathway, a signaling system normally mobilized to fight viral infections but increasingly implicated in chronic neurodegenerative disease. Alongside the interferon signature, the knockout microglia showed elevated expression of pro-inflammatory cytokines, the chemical messengers of inflammation, chemokines that recruit additional immune activity, and complement components, a branch of the immune system that has been linked to synapse loss in Alzheimer’s disease.

Type I interferon signaling has become one of the most intriguing threads in modern Alzheimer’s research. In the healthy brain, this pathway helps microglia respond rapidly to threats, but sustained or excessive activation can be damaging, promoting a chronic inflammatory environment that stresses neurons and disrupts synaptic connections. The new findings suggest that BIN1 normally acts as a molecular brake on this system, keeping the interferon response within bounds. When the protein is absent, the brake comes off, and the microglia respond to inflammatory signals with disproportionate vigor. This mechanism offers a concrete biological explanation for how a genetic risk factor identified through population genetics translates into cellular behavior inside the brain.

Perhaps the most compelling aspect of the study is its comparative analysis across species. The researchers compared the transcriptomic signature of the inflammation-induced Bin1cKO mouse microglia with gene expression data from human microglia in the early stages of Alzheimer’s disease. The comparison revealed genes showing similar trends of transcriptional change in both settings, suggesting that the inflammatory program unleashed by BIN1 deficiency in mice overlaps with the molecular changes occurring in human patients as the disease begins to take hold. This kind of cross-species convergence is a valuable benchmark, because animal models of Alzheimer’s disease have often been criticized for failing to capture the biology of the human condition. Here, the model appears to reproduce a disease-relevant inflammatory signature.

The implications of the work extend in several directions. For one, it reframes BIN1 not merely as a neuronal protein involved in tau biology and synaptic maintenance, but as a dual-function risk gene whose immune role may be equally important. If microglial BIN1 deficiency primes the brain for exaggerated inflammatory responses, then individuals carrying BIN1 risk variants could be more susceptible to inflammatory triggers throughout life, from infections to age-related immune changes. This resonates with a broader theme in Alzheimer’s research, in which cumulative inflammatory insults are thought to lower the threshold for disease onset. It also raises the possibility that therapies aimed at dampening type I interferon signaling or complement activation could be particularly beneficial in carriers of BIN1 risk alleles, an idea that would need to be tested in future studies.

Technically, the study demonstrates the power of combining cell-type-specific genetics with single-cell transcriptomics. By coupling a conditional knockout strategy to single-nucleus RNA sequencing, the researchers could dissect the contribution of a single gene in a single cell population while still capturing the full complexity of the brain’s cellular ecosystem. The phenotypic analyses of microglial morphology and the flow cytometry work, supported by the FACS Unit of the Hellenic Pasteur Institute, complemented the sequencing data by confirming that the transcriptional changes translated into visible alterations in cell structure and state. This multi-layered approach is increasingly seen as the standard for rigorous neuroimmunology, where gene expression alone can be misleading without corresponding cellular and functional validation.

There remain open questions. The study establishes that microglial BIN1 restrains inflammatory activation, but the precise molecular pathways through which the adaptor protein exerts this control, potentially involving its known roles in membrane dynamics and intracellular trafficking, have yet to be fully mapped. It is also unclear whether restoring BIN1 expression in microglia could reverse the heightened inflammatory state, or whether the effects of its loss during development are irreversible. What the research does establish, however, is a clear and testable principle: microglial BIN1 acts as a critical brake on inflammatory activation, and its deficiency shapes inflammatory susceptibility in a context directly relevant to Alzheimer’s disease. As the search for effective Alzheimer’s therapies continues, genes like BIN1 that sit at the intersection of genetic risk and immune regulation are likely to attract growing attention, both as clues to the disease’s origins and as potential targets for intervention.

Subject of Research: The role of the Alzheimer's genetic risk factor BIN1 in regulating microglial inflammatory activation and neuroinflammation

Article Title: Microglial deficiency of Alzheimer’s genetic risk factor Bin1 elicits enhanced cortical inflammatory response

Article References: Margariti, M., Thanou, I., Papadimitriou, E., Pelletier, A., Xingi, E., Antoniou, C., Kyrargyri, V., Costa, M. R., & Thomaidou, D. (2026). Microglial deficiency of Alzheimer’s genetic risk factor Bin1 elicits enhanced cortical inflammatory response. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06434-4

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06434-4

Keywords: BIN1, Alzheimer's disease, microglia, neuroinflammation, type I interferon, single-nucleus RNA sequencing, conditional knockout, cytokines, chemokines, complement, GWAS risk factor, neurodegeneration